These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 2521511)

  • 1. Priming of D1-dopamine receptor responses: long-lasting behavioral supersensitivity to a D1-dopamine agonist following repeated administration to neonatal 6-OHDA-lesioned rats.
    Criswell H; Mueller RA; Breese GR
    J Neurosci; 1989 Jan; 9(1):125-33. PubMed ID: 2521511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
    Breese GR; Duncan GE; Napier TC; Bondy SC; Iorio LC; Mueller RA
    J Pharmacol Exp Ther; 1987 Jan; 240(1):167-76. PubMed ID: 3100767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological evaluation of SCH-12679: evidence for an in vivo antagonism of D1-dopamine receptors.
    Breese GR; Criswell HE; McQuade RD; Iorio LC; Mueller RA
    J Pharmacol Exp Ther; 1990 Feb; 252(2):558-67. PubMed ID: 1968972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
    Hu XT; White FJ
    Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the D1-dopamine agonists SKF-38393 and A-68930 in neonatal 6-hydroxydopamine-lesioned rats: behavioral effects and induction of c-fos-like immunoreactivity.
    Johnson KB; Criswell HE; Jensen KF; Simson PE; Mueller RA; Breese GR
    J Pharmacol Exp Ther; 1992 Aug; 262(2):855-65. PubMed ID: 1354257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of D1 and D2 dopamine receptor stimulation on the activity of substantia nigra pars reticulata neurons in 6-hydroxydopamine lesioned rats: D1/D2 coactivation induces potentiated responses.
    Weick BG; Walters JR
    Brain Res; 1987 Mar; 405(2):234-46. PubMed ID: 2952219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine agonist-induced locomotor activity in rats treated with 6-hydroxydopamine at differing ages: functional supersensitivity of D-1 dopamine receptors in neonatally lesioned rats.
    Breese GR; Napier TC; Mueller RA
    J Pharmacol Exp Ther; 1985 Aug; 234(2):447-55. PubMed ID: 3926987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term D1-dopamine receptor sensitization in neonatal 6-OHDA-lesioned rats is blocked by an NMDA antagonist.
    Criswell HE; Mueller RA; Breese GR
    Brain Res; 1990 Apr; 512(2):284-90. PubMed ID: 2162235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lesions of the nigrostriatal dopamine projection increase the inhibitory effects of D1 and D2 dopamine agonists on caudate-putamen neurons and relieve D2 receptors from the necessity of D1 receptor stimulation.
    Hu XT; Wachtel SR; Galloway MP; White FJ
    J Neurosci; 1990 Jul; 10(7):2318-29. PubMed ID: 1973947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence that D-1 dopamine receptors contribute to the supersensitive behavioral responses induced by L-dihydroxyphenylalanine in rats treated neonatally with 6-hydroxydopamine.
    Breese GR; Baumeister A; Napier TC; Frye GD; Mueller RA
    J Pharmacol Exp Ther; 1985 Nov; 235(2):287-95. PubMed ID: 3932640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Priming of a D1 dopamine receptor behavioural response is dissociated from striatal immediate-early gene activity.
    Paul ML; Currie RW; Robertson HA
    Neuroscience; 1995 May; 66(2):347-59. PubMed ID: 7477877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Supersensitized D1 receptors mediate enhanced oral activity after neonatal 6-OHDA.
    Kostrzewa RM; Gong L
    Pharmacol Biochem Behav; 1991 Jul; 39(3):677-82. PubMed ID: 1686103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prior D1 dopamine receptor stimulation is required to prime D2-mediated striatal Fos expression in 6-hydroxydopamine-lesioned rats.
    Pollack AE; Yates TM
    Neuroscience; 1999; 94(2):505-14. PubMed ID: 10579212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ontogenetic quinpirole treatments fail to prime for D2 agonist-enhancement of locomotor activity in 6-hydroxydopamine-lesioned rats.
    Brus R; Kostrzewa RM; Nowak P; Perry KW; Kostrzewa JP
    Neurotox Res; 2003; 5(5):329-38. PubMed ID: 14715452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of the substantia nigra in the expression of dopamine D1 receptor-mediated and D2 receptor-mediated behaviours.
    Fletcher GH; Starr MS
    Neuroscience; 1987 Dec; 23(3):1001-10. PubMed ID: 2963970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of chronic SCH23390 treatment on the biochemical and behavioral properties of D1 and D2 dopamine receptors: potentiated behavioral responses to a D2 dopamine agonist after selective D1 dopamine receptor upregulation.
    Hess EJ; Albers LJ; Le H; Creese I
    J Pharmacol Exp Ther; 1986 Sep; 238(3):846-54. PubMed ID: 3018223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histamine H3 receptor agonist- and antagonist-evoked vacuous chewing movements in 6-OHDA-lesioned rats occurs in an absence of change in microdialysate dopamine levels.
    Nowak P; Dabrowska J; Bortel A; Biedka I; Szczerbak G; Słomian G; Kostrzewa RM; Brus R
    Eur J Pharmacol; 2006 Dec; 552(1-3):46-54. PubMed ID: 17055481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Behavioral and biochemical expression of D1-receptor supersensitivity following SCH 23390 repeated administrations.
    Gandolfi O; Roncada P; Dall'Olio R; Montanaro N
    Brain Res; 1988 Jul; 455(2):390-3. PubMed ID: 2969768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is stimulation of both D1 and D2 receptors necessary for the expression of dopamine-mediated behaviors?
    White FJ; Bednarz LM; Wachtel SR; Hjorth S; Brooderson RJ
    Pharmacol Biochem Behav; 1988 May; 30(1):189-93. PubMed ID: 2902644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective D1 and D2 dopamine agonists differentially alter basal ganglia glucose utilization in rats with unilateral 6-hydroxydopamine substantia nigra lesions.
    Trugman JM; Wooten GF
    J Neurosci; 1987 Sep; 7(9):2927-35. PubMed ID: 3114439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.